Printer Friendly

Calcitonin nasal spray may preserve bone microarchitecture in older women.

BETHESDA, MD. -- Calcitonin nasal spray appears to preserve trabecular bone microarchitecture at the distal radius without substantially altering bone mineral density, Charles H. Chestnut III, M.D., reported at a meeting on bone quality.

In a 2-year, randomized, double-blind study of 91 women (average age 67), high-resolution MRI of the distal radius showed that calcitonin nasal spray preserved significantly more trabecular bone architecture than placebo.

Calcitonin preserved the volume, number, spacing, and thickness of trabecular bone, Dr. Chestnut wrote in a poster presentation at the meeting, sponsored by the National Institute for Arthritis and Musculoskeletal and Skin Diseases and the American Society for Bone and Mineral Research. Trabecular bone microarchitecture was significantly preserved in calcitonin patients, compared with placebo patients, despite loss of bone mineral density (BMD) at the distal radius or lumbar spine during the same period. In placebo patients, the number of trabeculae declined slightly at those sites even if the women had gained BMD.

The results are consistent with earlier reports showing that calcitonin spray was associated with reductions in osteoporotic fractures in postmenopausal women with a history of vertebral fracture, despite producing minimal increases in BMD, said Dr. Chestnut, professor of medicine and radiology at the University of Washington, Seattle.

Almost none of the measurements of BMD in the lumbar spine or midradius were significantly correlated with MRI measures of trabecular microarchitecture change, suggesting that "BMD is a poor marker for trabecular microarchitecture," he wrote. In the calcitonin group, trabecular microarchitecture in the lower trochanter was preserved, according to T2-MRI findings, regardless of whether patients lost or gained total hip BMD. By comparison, trabecular microarchitecture deteriorated in the placebo group. All women in the trial received calcium supplementation.

Dr. Chestnut reported that he has received research grants and consulting fees from Novartis Pharmaceuticals Corp., which funded the trial and manufactures calcitonin-salmon nasal spray (Miacalcin).
COPYRIGHT 2005 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Rheumatology
Author:Evans, Jeff
Publication:Internal Medicine News
Geographic Code:1USA
Date:Jul 15, 2005
Previous Article:Parathyroid hormone builds bone in osteoporosis.
Next Article:Consider fracture risk data in osteoporosis prescribing.

Related Articles
Calcitonin spray may preserve trabecular bone architecture.
When, how, and which one? Navigating the maze of osteoporosis drugs.
The only drug you should ever take for osteoporosis.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters